COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER

被引：0
|
作者：
Guan, X. [1 ]
Li, H. C. [1 ]
Xia, Y. [2 ]
Yang, Q. [2 ]
Ma, A. X. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Peoples R China
[2] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE197
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Loibl, Sibylle
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Geyer, Charles E.
    Untch, Michael
    Thery, Jean-Christophe
    Schwaner, Ingo
    Limentani, Steven
    Loman, Niklas
    Lubbe, Kristina
    Chang, Jenny C.
    Hatschek, Thomas
    Tesarowski, David
    Song, Chunyan
    de Haas, Sanne Lysbet
    Boulet, Thomas
    Lambertini, Chiara
    Wolmark, Norman
    NPJ BREAST CANCER, 2022, 8 (01)
  • [33] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Pienkowski, T.
    Drosik, K.
    Gyldmark, M.
    Aultman, R.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [34] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Sibylle Loibl
    Chiun-Sheng Huang
    Max S. Mano
    Eleftherios P. Mamounas
    Charles E. Geyer
    Michael Untch
    Jean-Christophe Thery
    Ingo Schwaner
    Steven Limentani
    Niklas Loman
    Kristina Lübbe
    Jenny C. Chang
    Thomas Hatschek
    David Tesarowski
    Chunyan Song
    Sanne Lysbet de Haas
    Thomas Boulet
    Chiara Lambertini
    Norman Wolmark
    npj Breast Cancer, 8
  • [35] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [36] Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
    Martinez-Garcia, J.
    Puertes Boix, A.
    Sanchez Henarejos, P.
    Jimenez Lucas, M. D.
    Sanchez Saura, A.
    Luengo, M.
    Carrillo Vicente, R.
    Martinez Ortiz, M. J.
    Balsalobre, J.
    de la Morena Barrio, P. D. L. M.
    Garcia Garre, E.
    Garcia, E.
    Marin, G.
    Garcia Torralba, E.
    Ayala de la Pena, F.
    Collado, D.
    Lopez, A.
    Quiros, T.
    Sanchez, D. A.
    Romero, J. L. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S358 - S358
  • [37] Cost-effectiveness of ado-trastuzumab emtansine (T-DM1) versus trastuzumab (H) for the adjuvant treatment of patients with residual invasive HER2+early breast cancer in the US
    Goertz, Hans-Peter
    Herrera-Restrepo, Oscar
    Wehler, Elizabeth
    Bilir, Pinar
    Antao, Vincent
    Jhuti, Gurleen Singh
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
    Baez-Vallecillo, L.
    Raghavendra, A. Singareeka
    Hess, K.
    Moulder, S. L.
    Tripathy, D.
    Valero, V.
    Murthy, R. K.
    CANCER RESEARCH, 2017, 77
  • [39] Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
    Dai, Wei Fang
    Beca, Jaclyn M.
    Nagamuthu, Chenthila
    Liu, Ning
    de Oliveira, Claire
    Earle, Craig C.
    Trudeau, Maureen
    Chan, Kelvin K. W.
    JAMA ONCOLOGY, 2022, 8 (04) : 597 - 606
  • [40] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
12345